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ABSTRACT
Introduction: There is a hypothesis that magnesium sulphate can provide relief from headaches caused by migraine. In this
study, we have compared the effects of magnesium sulfate and dihydroergotamine (DHE) in the management of severe
migraine headaches. Methods: The study includes 120 patients who presented to our hospital's emergency room with
headache due to migraine. They randomly received either 100 ml normal saline solution with 1g of magnesium sulfate or
dihydroergotamine mesylate, which is standard acute migraine treatment. Patients evaluated their pain on the visual analogue
scale (VAS) at 30, 60 and 90 minutes after the intervention. Results: Thirty minutes after intervention, mean VAS was 6 ±
1.29 in the magnesium sulfate group and 5.85 ± 1.02 in the DHE group. Sixty minutes after intervention, it was 4.08 ± 1.67
(magnesium sulfate) and 4.62 ± 1.21 (DHE). While at 90 minutes it was 2.48 ± 1.61 (magnesium sulfate) and 3.48 ± 1.26
(DHE). Pain score comparisons were statistically significant at 60 and 90 minutes, although not at 30 minutes. The two groups
were similar in terms of gender distribution and migraine subtype. Conclusion: Treatment with 1g of magnesium sulfate in
100 ml normal saline solution provides significant pain relief in migraine without any serious side effects.

Heada che att acks a re o ne o f the mo st c om mon
complaints presenting to the emergency room, 1 w i t h
women twice as likely to present with migraine headaches
as compared to men. 2 Dihydroergotamine (DHE) is
commonly used for pain relief during acute migraine, but
this drug has limiting side effects, such as nausea and
vomiting.3 Research for drugs or components that relieve
pain during a severe attack without side effects is ongoing.
Magnesium deficiency has been postulated to play a role
in migraine pathophysiology,4 and it is hypothesized that
magnesium sulfate can provide relief from headaches
caused by migraine. In this study, the therapeutic effects
of magnesium sulfate in acute migraine were compared
with the beneficial effects of DHE.

was obtained from all patients. Age of less than 15 years,
allergic reaction to magnesium sulfate, abnormal findings
in physical examination, blood calcium level less than 8.3
mg/dl, and presence of cardiac or renal problems were the
exclusion criteria for the study. Patients randomly received
either 1g magnesium sulfate in 100 ml normal saline
solution or DHE (standard treatment of acute migraine).
Patients and the treating physician were blinded to the
tre atm ent t ype use d f or ea ch p at ie nt, wi th t he
identification code assigned to each case kept confidential
until after the primary analysis. Patients evaluated their
pain on the visual analogue scale (VAS) with endpoints of
none and greatest pain.0-10 The patients were requested
to evaluate their pain on the VAS again at 30, 60 and 90
minutes after receiving the intervention. Statistical
analysis employed t-test and chi-square test, with the
level of significance set at 95%.

METHODS
The study was conducted in the emergency department of
Shahid Sadoughi Hospital (Yazd, Iran) between March and
November 2006. A sample of 120 patients (60 in each
group) presenting with headache due to migraine were
included. The study protocol was reviewed and approved
by the University's Ethics Committee and informed consent
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RESULTS
Of 120 patients enrolled in the study, 80 (66.7%) were
female and 40 (33.3%) male. Classic migraine was
present in 47 patients (39.2%), while 73 patients
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(60.8%) had common pattern migraine. Mean serum
magnesium level before intervention was 1.99 ± 0.81
mg/dl, while mean serum calcium level before intervention
was 9.10 ± 0.83 mg/dl.
Table 1: Comparison between mean and standard deviation of VAS at 0.5, 1
and 1.5 hours after intervention in both study groups

VAS
0.5 hours after 1 hour after 1.5 hour after
intervention
intervention intervention

Group of study

Magnesium
Sulfate

Dihydroergotamine

Total

Number
Mean
S.D

60
6
1.29

60
4.08
1.67

60
2.48
1.61

Number
Mean
S.D

60
5.85
1.02

60
4.62
1.21

60
3.48
1.26

Number
Mean
S.D

120
5.93
1.16

120
4.35
1.47

120
2.98
1.52

Magnesium

Ergotamine

Figure 2: Mean and confidence interval of VAS in
both group of study at 90 min after intervention

(P-value = 0.48 for 0.5 hour, P-value = 0.047 for 1 hour, P-value = 00.0 for 1.5 hours
after trial)

Tables 1 and 2 summarize the VAS results. At 30 minutes
after intervention, mean VAS was 6 ± 1.29 in the
magnesium group and 5.85 ± 1.02 in the DHE group,
which changed to 4.08 ± 1.67 (magnesium group) and
4.62 ± 1.21 (DHE group) at 60 minutes, and 2.48 ±
1.61 (magnesium group) versus 3.48 ± 1.26 (DHE
group) at 90 minutes (p < 0.01) . A significant reduction
in pain intensity at 60 and 90 minutes after treatment,
compared with baseline, was seen in both groups (at 60
min, p = 0.047; at 90 min, p < 0.01). Mean VAS of
patients in the magnesium group was significantly lower
than the ergotamine group. This reduction in pain intensity
was not different between the groups at 30 minutes after
intervention (p = 0.48; figures 1 and 2)

Magnesium

Figure 1: Mean and confidence interval of VAS in
both group of study at 60 min after intervention

Patients were also divided into two groups according to
their baseline magnesium level (above or below 1.5).
There were significant differences between mean VAS
score at 60 and 90 minutes after intervention among the
two groups (p = 0.004 for 60 min; p < 0.01 for 90 min).
At 30 minutes, however, the scores in both groups were
similar (Table 3). VAS scores also did not differ according
to gender (Table 2) or migraine type.

Table 2: Comparison between mean and standard deviation of VAS at 0.5, 1
and 1.5 hours after intervention in both sex groups

VAS
0.5 hours after 1 hour after 1.5 hour after
intervention
intervention intervention

Group of study

Male

Female

Total

Number
Mean
S.D

40
5.97
1.33

40
4.55
1.57

40
3.10
1.52

Number
Mean
S.D

80
5.90
1.07

80
4.25
1.43

80
2.93
1.53

Number
Mean
S.D

120
5.92
1.16

120
4.35
1.48

120
2.98
1.52

DISCUSSION
Increasing evidence supports a role for both systemic and
brain magnesium deficiency in patients with migraine,
especially migraine localized to the occipital lobes.
Magnesium normally maintains a strongly coupled state of
mitochondrial oxidative phosphorylation. It also plays a
role in gating the N-methyl-D-aspartate (NMDA) subtype
of glutamate receptors. Magnesium deficiency causes

(P-value = 0.74 for 0.5 hour, P-value = 0.29 for 1 hour, P-value = 0.56 for 1.5 hours after
trial)
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or the establishment he represents; and the culture and
expectation of patients. 10 In chronic diseases such as
migraine, prior treatment history may influence patients'
expectation of the pain relief properties of drugs. The
route of administration of a drug can also influence the
relief response, possibly as an augmentation of the
placebo effect.

Table 2: Comparison between mean and standard deviation of VAS at 0.5, 1
and 1.5 hours after intervention according to magnesium level of patients
before intervention

VAS
0.5 hours after 1 hour after 1.5 hour after
intervention
intervention intervention

Group of study
Magnesium
less than 1.5
mg/dl

Number
Mean
S.D

21
5.71
1.15

21
3.52
1.40

21
1.57
1.08

Magnesium
more than
1.5 mg/dl

Number
Mean
S.D

99
5.70
1.16

99
4.53
1.44

99
3.28
1.44

Total

Number
Mean
S.D

120
5.93
1.16

120
4.35
1.48

120
2.98
1.52

Bigal and colleagues have reported that magnesium
sulfate can reduce all symptoms in migraine with or
without aura.11 Other investigators have reported that a
disturbance in magnesium ion homeostasis in the brain
underlies the pathogenesis of migraine disease. 1 2
L ite rat ur e rep or ts in di cate th at 1 g i nt rav en ou s
magnesium sulfate is an efficient, safe, and well tolerated
drug for the treatment of migraine attacks. It is possible
that magnes ium sulfate may be used in a broader
spectrum of patients other than those in the acute attack
phase.13

(P-value = 0.36 for 0.5 hour, P-value = 0.004 for 1 hour, P-value = 0.00 for 1.5 hours after
trial)

instability of neuronal polarization because of a loss of
ionic homeostasis, leading to neuronal hyperexciitability
and a lower threshold for spontaneous depolarization.5

Our results are subject to certain limitations. We enrolled
all patients presenting with migraine headache regardless
of a prior history of migraine or any co-morbid conditions.
We also did not ask about symptoms associated with
migraine (such as photophobia or nausea) and relied
exclusively on pain relief as the sole outcome measure.
The study did not conduct follow-up assessments beyond
90 minutes, and the long-term beneficial of magnesium
be yo nd t hi s du rat ion, i f an y, ar e u nkn own. Fo r
confirmation of our results, the effect of magnesium
sulfate in acute migraine should be examined in largescale studies.

M ig ra in e patho phy si ol o gy re mai ns i nco mp lete ly
understood. Evidence suggests that vascular components
play a basic role in the pathophysiology of migraine. Our
s tud y ha s sho wn m a gn esium ad mi nist r at ion as a
treatment strategy for migraine. The results of our study
show that 100 ml normal saline solution with 1 g of
magnesium sulfate provided significant pain relief in
migraine headache attacks presenting to the ER. It is
important to note that these effects were most noticeable
at 60 and 90 minutes and were not appreciated at 30
minutes after intervention. Mauskop and Altura have
reported that around 50% of migraineurs had low levels of
magnesium during migraine attacks. Magnesium infusion
causes rapid and continuous relief during migraine
attacks.4,6
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